ReviewPrenatal diagnosis2026
The Sooner, the Better: Neuroprotective Strategies in Fetuses With Congenital Heart Disease.
Review in Prenatal diagnosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Congenital heart disease (CHD) is the most frequent congenital malformation at birth and is associated with neurodevelopmental impairments. Alterations in cardiovascular physiology can lead to reduced cerebral blood perfusion and oxygenation, which negatively affects brain growth and maturation. Advanced imaging studies indicate that these aberrations in brain development can manifest as early as in utero, resulting from the inability of the fetal circulatory system to meet the increased metabolic demands of the brain. Fetal brain dysmaturation increases the susceptibility to postnatal brain injury and is related to adverse long-term neurodevelopmental outcomes throughout childhood. This emphasizes the potential for effective prenatal neuroprotective strategies in fetuses with CHD, as optimization of their intrauterine environment may prevent irreversible neurological damage and minimize long-term neurodevelopmental comorbidities. This review provides a comprehensive overview of prenatal neuroprotective strategies in fetuses with critical CHD, including in utero therapeutic interventions, prenatal surgical cardiac interventions, and modifiable prenatal and perinatal risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.